Recommendation of the President – Opdivo (nivolumab)

On 3 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 188/2025 on the reimbursement of the medicinal product Opdivo (nivolumab) under the B.4. drug program. “Treatment of patients with colorectal cancer (ICD-10: C18-C20)”

Publication in Public Information Bulletin (BIP) >>